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RESULTS: Two months after stroke informal caregivers
spent 22.7 hours a week (mean) on a range of different care
tasks. Six months after stroke they spent 25.1 hours a week
(mean) on the same tasks. Their mean EQ-5 score is 0.836
(n  195) after two months and 0.816 (n  138) after six
months. After two months 40 percent reports pain and
other complaints and 25 percent reports anxiety. Six
months after stroke this is respective 45 percent and 25 per-
cent. Health related quality of life results and time invested
will be compared to the general population by sex and age.
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Current cost-effectiveness models of antibiotic efficacy
typically do not consider the variability in relative inci-
dence of infectious agents or the probability of species-
specific antibiotic resistance. A model that incorporates
this variability in incidence and resistance will more accu-
rately represent epidemiological variances and associated
differences in treatment costs across patient populations.
OBJECTIVES: To create a model of antibiotic efficacy
that generates population-specific cost-effectiveness ra-
tios by including incidence and resistance rates of infec-
tious agents and can be adjusted to reflect epidemiologi-
cal data specific to different geographic regions.
METHODS: We constructed a decision tree model that
represents a user-defined infection (i.e. acute exacerba-
tion of chronic bronchitis). This model considers the rela-
tive incidence of infectious agents (bacterial and non-
bacterial/viral), the incidence of resistance among the
bacteria agents, and antibiotic efficacy against each infec-
tious agent and level of resistance. The model can repre-
sent “all-or-none” resistance such as that associated with
beta-lactamase production, or varying degrees of suscep-
tibility associated with other methods of resistance. The
model can represent clinical or in vitro efficacy, depend-
ing on the source of the data. In the event of insufficient
data to populate the resistance branch, this branch can be
collapsed out of the tree. The model will then represent
antibiotic efficacy for all infectious agents included.
RESULTS: The model generates cost-effectiveness ratios
identifying conditions where the antibiotic of interest is
cost effective or cost saving versus other antibiotics. Ra-
tios for individual infectious agents and levels of resis-
tance also identify specific populations where the antibi-
otic of interest has an advantage.
CONCLUSIONS: This model can incorporate geographic
diversity of and resistance in bacterial populations to gen-
erate cost-effectiveness ratios specific to different epidemi-
ological and geographic populations.
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OBJECTIVES: Preventive therapy has been accepted as a
standard protocol to reduce morbidity and mortality
from tuberculosis in HIV-infected patients. Conventional
cost-effectiveness analyses attempt to assess superiority
of one therapy over another in terms of monetary benefit.
The present study tries to determine variables that are not
considered in conventional cost-effectiveness analyses but
which are likely to have significant impact on disease out-
come.
METHODS: Based on MEDLINE search, compilation
and analysis of cost-effectiveness analyses of preventive
therapy for tuberculosis in HIV-infected populations
from 1995 to 2001.
RESULTS: Standard preventive therapies employed are:
isoniazid daily for six months; rifampicin plus pyrazina-
mide twice weekly for two months; isoniazid plus
rifampicin daily for three months. Variables considered
were medical care costs, social costs and cost per QALY
saved, i.e., which can be measured in terms of monetary
benefit. Isoniazid has been considered the most cost-
effective option. Important variables not considered were
risk of resistance—primary (isoniazid resistance 16.67%,
rifampicin 6.67%) or secondary (isoniazid resistance
61.76%, rifampicin 70.59%)—to the same patient upon
diagnosis of active tuberculosis and/or to the community
exposed; morbidity from adverse drug reactions and drug
interactions with anti-retroviral drugs.
CONCLUSIONS: Indiscriminate prophylaxis can in-
crease the chances of primary and secondary resistance
and morbidity from adverse drug reactions and drug in-
teractions. Study models to include these variables in
conventional cost-effectiveness analyses are needed to as-
sess the actual benefit of preventive therapy.
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OBJECTIVE: This paper presents a model based on real-
option analysis for evaluation of R&D in the pharmaceu-
tical sector, both for start-up ventures as well as for big
conglomerates. The analysis will be illustrated by means of
a case study and shows the valuable contribution of real-
option analysis compared to conventional DCF-analysis.
METHODS: The key understanding is that R&D projects
can be seen as growth options. The growth-option frame-
work looks at pharmaceutical investment projects as a
sequence of options, which differs from a conventional
DCF-analysis by incorporating the possibility of stopping
the project when a subsequent phase is not valuable (aban-
don the option), and of continuing the project (exercise the
option) when it is valuable. Traditional valuation tech-
niques such as DCF-analysis fail to fairly evaluate innova-
tive companies because most of the value of R&D projects
is embedded in unexercised real options whose future
value is uncertain at this moment. If one considers a com-
pany as a portfolio of real options, one can value the
projects or the company based on an option model.
RESULTS: The case study illustrates that real-option
analysis typically results in a higher project value than
conventional DCF-analysis would reveal. Real-option
analysis better reflects the fundamental value of the
project or of the company, which cannot be captured by
DCF-analysis.
CONCLUSION: This paper presents a new methodology
for evaluating pharmaceutical R&D based on real-option
models. As such, the real-option framework is better in
explaining the recent stock price behavior of biotech and
pharmaceutical firms.
PMI21
ESTIMATING INFLUENZA-RELATED EXCESS 
HOSPITAL ADMISSIONS
Scuffham P1, Piercy J2
1York University, York, UK; 2Mapi Values, Macclesfield, UK
OBJECTIVES: It is difficult to accurately assess the im-
pact of influenza on hospital admissions. Most influenza
admissions are not coded as such, since the reason for ad-
mission is usually an underlying condition exacerbated
by influenza. The difficulty of assessing the excess burden
is complicated by the nature of commonly associated
conditions such as pneumonia, heart failure, and respira-
tory disease, all of which exhibit similar seasonal varia-
tions in numbers of hospitalizations. The objective is to
remove the seasonal variation to estimate the fluctuations
attributed to influenza during epidemic periods.
METHODS: We used a structural time series model that
included a stochastic trend and a trigonometric seasonal
function. Dummy variables (1 during influenza epidemic,
otherwise 0) were used to capture the excess hospitaliza-
tions over and above those that occur due to typical sea-
sonal fluctuation. Weekly hospital data on pneumonia
and influenza, all other respiratory conditions, and con-
gestive heart failure were modeled for public hospitals in
England and Wales.
RESULTS: The models explained between 72% and
95% of the variation in hospital admissions for the rele-
vant diagnostic groups (except CHF, explained variance
43%). We found a one-week lag in two models reflecting
the time elapsed between diagnosis and admission. Mean
numbers of excess admissions over a 10-year period were:
high risk 17,857 (range 12,779–26,104); elderly 17,856
(10,869–28,966); adult 4,820 (3,175–7,453).
CONCLUSIONS: Estimation of the burden of excess
hospitalizations must take account of underlying sea-
sonal variations. Traditional methods of estimation, such
as comparing epidemic and non-epidemic periods, are of
limited value. Furthermore, because much of the excess
hospital burden of influenza can be hidden (admission
codes reflect underlying conditions or complications), it
is necessary to take into account the variations in a wide
range of conditions.
